09.09.19

EyePoint Pharmaceuticals Announces Data Highlighting Yutiq to be Presented at Retina Society Scientific Meeting

Source: EyePoint Pharmaceuticals

EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for chronic, noninfectious uveitis affecting the posterior segment of the eye have been accepted for two oral presentations at the 52nd Annual Retina Society Scientific Meeting being held September 11-15, 2019 in London.

“The US commercial launch of Yutiq has received strong support and reception from uveitis specialists,” Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals, said in a company news release. “Physicians continue to cite the durable, 36-month follow up Phase 3 data of Yutiq as an innovative advance to the current treatment options due to its long-lasting activity and convenient, consistent dosing. We believe Yutiq is well-positioned to address the treatment limitations and unmet need associated with chronic, non-infectious uveitis affecting the posterior segment of the eye and anticipate increasing penetration within this historically underserved patient community.”

Details for the Retina Society presentations are as follows:

Title: The Use of Adjunctive Anti-inflammatory Medications: Results from a 3 Year Study of a Fluocinolone Acetonide Intravitreal Insert in Chronic Non-Infectious Uveitis Affecting the Posterior Segment
Presenter: Dilraj Grewal, MD, Associate Professor of Ophthalmology, Duke Eye Center
Session Title: Inflammation 
Date and Time: Sunday, September 15, 2019, 11:52-11:58 AM BST

Title: Minimizing Uveitic Recurrences: Results from a 36M Study of Fluocinolone Acetonide Intravitreal Insert in Subjects with Chronic Non-Infectious Uveitis Affecting the Posterior Segment
Presenter: Thomas Arno Albini, MD, Professor of Clinical Ophthalmology, Bascom Palmer Eye Institute
Session Title: Inflammation 
Date and Time: Sunday, September 15, 2019, 12:02-12:08 PM BST

Related Content